ITDD awarded new NIH grants

Publication date: 
Wednesday, December 11, 2019

The Institute for Therapeutics Discovery and Development (ITDD) has been awarded a new NIH contract entitled "Support for NCATS Medicinal Chemistry for Lead Optimization". The objective of this contract is to support the NIH National Center for Advanced Translational Sciences (NCATS) drug development programs by identifying preclinical drug candidates with improved efficacy, optimized ADME properties, and minimal predicted toxicity. The potential value of this five-year contract is $17,887,012. The program is led by Dr. Vadim J. Gurvich, associate director of the ITDD, who serves as principal investigator. Dr. Gunda I. Georg, ITDD director and Regents Professor, serves as co-principal investigator and other ITDD directors, Drs. Michael A. Walters, Jon Hawkinson, and Henry Wong serve as investigators.

Dr. Vadim J. Gurvich and the Institute for Therapeutics Discovery and Development (ITDD) have been awarded a new NIH contract entitled "Synthesis of (-)-Phenserine Tartrate Clinical Grade Material". The objective of this contract is to support the NIH National Institute of Aging (NIA) clinical development of (-)-phenserine for the treatment of Alzheimer's disease. The total value of this contract is $150K for one year. This is the third NIH contract that Dr. Gurvich received in recent years to support these studies.